{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The incidence of regimen-related mortality in the first 100 days post-transplant is estimated based on binomial distribution.","groups":[{"description":"Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.","id":"OG000","title":"High-Risk Hematologic Malignancies"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days post-transplant","title":"Incidence of Regimen-related Mortality","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}